Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021

HomePrecision Spine Inc.National Launch of the ShurFit® 2C Interbody Systems Featuring Titanium Plasma Spray and Hydroxyapatite Coating

National Launch of the ShurFit® 2C Interbody Systems Featuring Titanium Plasma Spray and Hydroxyapatite Coating

Precision Spine, Inc. has launched nationally the ShurFit® ACIF 2C Anterior Cervical, TLIF 2C, and TPLIF 2C Posterior Interbody Systems, which is made from medical grade polyetheretherketone (Peek Optima, LT1) and coated with both commercially pure Titanium (Ti) and Hydroxyapatite (HA).

“The ShurFit 2C Interbody System’s distinguishing feature is its unique coating of both Titanium and Hydroxyapatite that helps increase durability and makes enhanced fixation possible while the process of biologic fusion takes place,” said Stephen D. Cook, Ph.D., Executive Director and Founder of the Fellowship of Orthopaedic Researchers, who was instrumental in the design and development of the device with Precision Spine engineers.

The ShurFit 2C coating technology combines a high-strength PEEK core with a unique, dual layer of coatings applied directly to the endplate surfaces. A biocompatible plasma-sprayed CP Titanium coating, with an outer layer of osteoconductive Hydroxyapatite, provides an optimal environment for osseointegration. The dual coating promotes rapid bone formation, which offers implant stability, less potential for implant migration, and the formation of a stable fusion mass while strategically placed tantalum markers facilitate radiographic implant positioning.

“The ShurFit ACIF 2C Systems are an important addition to our growing portfolio of devices,” said Chris DeNicola, Chief Operating Officer of Precision Spine, “and is further evidence of Precision Spine’s continuing commitment to work with surgeons in the design and commercialization of advanced products that utilize the latest technology to help bring greater versatility, efficiency, and cost-effectiveness to the OR.”

The ShurFit ACIF 2C system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine at one disc level and consists of implants with various heights to accommodate individual patient anatomy and graft material size. It is implanted from the anterior approach at the C3 to C-7 disc levels and is designed to be packed with autogenous bone graft to help facilitate fusion while providing mechanical support to the implanted level until biologic fusion is achieved.

The ShurFit TLIF 2C and TPLIF 2C Interbody Fusion Devices are indicated for intervertebral body fusion of the spine in skeletally mature patients. The device system is designed for use with autograft to facilitate fusion. One device is used per intervertebral space for the TLIF 2C and TPLIF 2C system. Two devices are used per intervertebral space for the PLIF 2C system.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy